Coronavírus Página 5

WHO - COVID-19 Clinical management: living guidance

World Health OrganizationProviding trustworthy guidance that is comprehensive and holistic for the optimal care of COVID-19 patients, throughout their entire illness is necessary. The previous version of the Clinical management of COVID-19...

AMP - SARS-CoV-2 and Cancer: Beyond Immunosuppression

Acta Médica PortuguesaOver the last year the COVID-19 pandemic has led to more than 83 million cases and 1.8 million deaths worldwide. Several conditions, such as cancer, have been identified as potential risk factors for poor outcomes of...

WHO - Contact tracing in the context of COVID-19

World Health OrganizationContact tracing is a key strategy for interrupting chains of transmission of SARS-CoV-2 and reducing COVID-19-associated mortality. This document provides updated guidance on how to establish contact tracing capacity for...

DGS - Campanha de Vacinação Contra a COVID-19 – Fase 1

Direção-Geral da SaúdeA COVID-19 é uma doença potencialmente evitável. Apesar da evidência científica relativa à história natural da doença, ao desenvolvimento de imunidade protetora e à sua duração após a infeção por SARS-CoV-2 ser ainda...

AMP - The Role of Pharmacovigilance in the COVID-19 Pandemic

Acta Médica PortuguesaA farmacovigilância foi definida pela Organização Mundial da Saúde como a ciência e as atividades relacionadas com a deteção, avaliação, compreensão e prevenção de eventos adversos ou qualquer outro problema de segurança...

WHO - Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 placebo-controlled vaccine trials and trial unblinding

World Health OrganizationThe conduct of COVID-19 vaccine trials in the context of a candidate vaccine being issued with Emergency Use Designation raises challenging ethical questions, including in relation to the use of placebo controls and...

WHO - mRNA-1273 vaccine (Moderna) against COVID-19 Background document (draft)

World Health OrganizationThe messenger ribonucleic acid (mRNA) vaccine platform has advantages as a pandemic-response strategy, given its efficiency in immunogen design and manufacturing. As mRNA is a non-infectious, non-integrating platform,...

AMP - COVID-19 Vaccine: From Theory to Practice

Acta Médica PortuguesaDesde o primeiro diagnóstico de COVID-19 em Wuhan, até à data atual, foram infetadas pelo vírus SARS-CoV-2, a nível mundial, mais de 64 milhões de pessoas, causando mais de 1,5 milhões de óbitos.1 Desde que foi reconhecida...

ECDC - Risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA – first update

European Centre for Disease Prevention and ControlViruses constantly change through mutation and variations in the SARS-CoV-2 virus, due to evolution and adaptation processes, have been observed worldwide. While most emerging mutations will not...

WHO - Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing

World Health Organization

This interim guidance has been developed based on the advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) at its 5 January 2021 extraordinary meeting.

AMP - Influenza Vaccination in Patients with Cardiovascular Disease Under 65 in the COVID-19 Era

Acta Médica Portuguesa

Sabemos que a vacinação contra o vírus influenza nos doentes com patologia cardiovascular reduz significativamente o número de eventos cardiovasculares major e a mortalidade cardiovascular.

THE LANCET - 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

The LancetThe long-term health consequences of COVID-19 remain largely unclear. The aim of this study was to describe the long-term health consequences of patients with COVID-19 who have been discharged from hospital and investigate the...

NEJM - Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

The New England Journal of MedicineTherapies to interrupt the progression of early coronavirus disease 2019 (Covid-19) remain elusive. Among them, convalescent plasma administered to hospitalized patients has been unsuccessful, perhaps because...

NICE - COVID-19 rapid guideline: managing the long-term effects of COVID-19

National Institute for Health and Care ExcellenceThis guideline covers identifying, assessing and managing the long-term effects of COVID-19, often described as ‘long COVID’. It makes recommendations about care in all healthcare settings for...

NEJM - Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

The New England Journal of MedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective...